For low grade IDH mutant gliomas the treatment paradigm has shifted from the traditional approach of surgery followed by active surveillance or adjuvant radiation and/or chemotherapy based on recurrence risk, to the incorporation of IDH inhibitors (Mohile et al., 2022; Weller et al., 2021; Miller et al., 2023). The gene discussed is IDH1; the disease is central nervous system cancer.